View Older Stories View More Recent Stories

Jun 14, 2017 01:15PM Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
Jun 13, 2017 09:00AM Nearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey
Jun 13, 2017 08:02AM Pfizer (PFE) and Lilly (LLY) Announce FDA Fast Track Designation for Tanezumab
Jun 13, 2017 08:00AM Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
Jun 10, 2017 01:00PM Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies
Jun 7, 2017 07:33AM Sangamo Biosciences (SGMO) & Pfizer (PFE) Granted Orphan Medicinal Product Designation from European Medicines Agency for SB-525 Investigational Hemophilia A Gene Therapy
Jun 7, 2017 07:30AM Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
Jun 6, 2017 08:01AM Pfizer (PFE) Receives FDA Fast Track Designation for Tafamidis to Treat TTR-CM
Jun 6, 2017 08:00AM Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy
Jun 3, 2017 04:30PM Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
May 31, 2017 08:33AM Pfizer (PFE) sNDA for SUTENT Accepted by FDA, EMA; January 2018 PDUFA
May 31, 2017 08:30AM Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT® (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell C
May 30, 2017 10:01AM Pfizer (PFE) Announces EC Approval for TRUMENBA to Help Prevent Meningococcal Group B Disease in Adolescents and Adults
May 30, 2017 10:00AM European Commission Approves Pfizer’s TRUMENBA® to Help Prevent Meningococcal Group B Disease in Adolescents and Adults
May 25, 2017 01:20PM Pfizer (PFE) Announces FDA AdCom Recommendation for Epogen/Procrit Biosimilar
May 25, 2017 01:16PM FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications
May 24, 2017 06:45AM Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation
May 17, 2017 08:00PM Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting
May 10, 2017 04:03PM Sangamo Biosciences (SGMO), Pfizer (PFE) Enter Pact on Hemophilia A Gene Therapy
May 10, 2017 04:01PM Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy
May 9, 2017 03:56PM Merck KGaA, Pfizer (PFE) Announce FDA Approval for BAVENCIO for Common Type of Advanced Bladder Cancer
May 9, 2017 03:53PM FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
May 8, 2017 10:00AM Collaboration Helps Broaden Access to Pfizer’s Contraceptive, Sayana® Press (medroxyprogesterone acetate), for Women in Some of the World’s Poorest Countries
May 3, 2017 05:25PM Phase 3 OCTAVE Studies of Oral Tofacitinib in Ulcerative Colitis Results Published in The New England Journal of Medicine
May 3, 2017 09:02AM Pfizer (PFE) Announces FDA Filing Acceptance of sNDA for XELJANZ to Treat Adults with PsA
May 3, 2017 09:00AM Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis
Apr 27, 2017 12:30PM Pfizer Hosts Annual Meeting of Shareholders
Apr 27, 2017 09:08AM InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury
Apr 27, 2017 08:06AM Pfizer's (PFE) Lorlatinib Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic NSCLC
Apr 27, 2017 08:00AM Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer
Apr 24, 2017 05:56AM Pfizer (PFE) Announce Topline Phase III Study Results for Efficacy Of Zavicefta (Ceftazidime-Avibactam) for Treatment Of Hospital-Acquired Pneumonia
Apr 24, 2017 05:30AM Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals
Apr 21, 2017 03:07PM Pfizer (PFE) Announces Positive CHMP Opinion for BESPONSA to Treat Relapsed/Refractory ALL
Apr 21, 2017 03:05PM Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Apr 21, 2017 08:36AM Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries
Apr 18, 2017 05:52AM Pfizer (PFE) & HitGen Report 4-yr Agreement to Build and Screen Novel DNA-Encoded Libraries
Apr 18, 2017 03:12AM HitGen and Pfizer Enter Research Collaboration and License Agreement to Build and Screen Novel DNA-Encoded Libraries
Mar 31, 2017 02:06PM Pfizer (PFE) Announces Expanded FDA Approval for IBRANCE Indication for First-Line HR+, HER2- Metastatic Breast Cancer
Mar 31, 2017 02:04PM IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer
Mar 27, 2017 05:43AM Pfizer (PFE) Secures EC Marketing Authorization for Treatment of Rheumatoid Arthritis
Mar 27, 2017 05:00AM XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)
Mar 24, 2017 10:18AM Pfizer (PFE) Announces Positive CHMP Opinion for TRUMENBA for Prevention of Meningococcal Group B Disease
Mar 24, 2017 10:18AM Pfizer Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningococcal Group B Disease
Mar 23, 2017 05:35PM Pfizer (PFE) and Merck (MRK) BioPharma Unit Get FDA Approval for BAVENCIO® (Avelumab), the 1st Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Mar 23, 2017 05:30PM FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Mar 17, 2017 11:17AM Bristol-Myers Squibb (BMY), Pfizer (PFE) Present Analysis of Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation
Mar 17, 2017 11:15AM Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial
Mar 16, 2017 05:37AM Pfizer (PFE) Announces Approval of XELJANZ�® by the China FDA
Mar 15, 2017 09:00PM Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Mar 14, 2017 06:27AM Pfizer (PFE) Launches Zavicefta in the U.K. and Germany
View More Recent Stories View Older Stories